A signed order by Acting Attorney General Todd Blanche last month reclassified state-licensed medical cannabis to Schedule III under the Controlled Substances Act - a shift that immediately untethered medical operators from Section 280E of the Internal Revenue Code, the punitive tax provision that has long prevented cannabis businesses from deducting ordinary business expenses. The relief is substantial: industry data from analytics provider Headset puts the annual tax savings at roughly $268,000 per dispensary across 24 state markets, enough to push many previously unprofitable storefronts into the black. Adult-use operators, however, are still waiting - and what they're waiting on is a compressed administrative hearing process scheduled to begin June 29 and conclude by July 15.
The Section 280E Divide and What It Actually Means
Section 280E has functioned as a structural tax on cannabis businesses since the IRS began enforcing it against Schedule I and II controlled substances. Unlike any other retail business, cannabis operators could not deduct rent, payroll, marketing, or utilities - only the cost of goods sold. The effective tax rates that resulted were, in practice, confiscatory. A business reporting modest profits on paper could owe federal tax exceeding its actual net income.
Schedule III reclassification changes that calculus entirely for medical licensees. Starting Q1 2026, those operators can treat their businesses the way a pharmacy or a brewery does - deducting standard operating expenses and potentially seeking retrospective relief for prior tax years. That's not a minor accounting adjustment. For a mid-size dispensary carrying heavy overhead, it's the difference between viable and insolvent.
Here's the catch: "medical" and "adult-use" are regulatory categories, not consumer behavior categories. The same product, sold to the same person for the same reason, gets treated differently under federal tax law depending on which license type sits on the wall behind the counter. That asymmetry is now driving a rapid reconsideration of license structures across multiple states.
California's Shrinking Patient Market Gets a New Reason to Exist
California's Department of Cannabis Control moved quickly. On April 30, the DCC announced a streamlined process allowing cultivation licensees to change or add a medicinal-use (M) designation without waiting for renewal and, in many cases, without obtaining new local authorization. The agency explicitly connected this action to the federal rescheduling order - and noted that it had requested a briefing from the DEA, which declined, saying it would release information publicly and uniformly rather than in state-specific conversations.
The timing is pointed. California's medical cannabis market peaked above $2.5 billion in annual sales in 2017; by 2025, that figure had collapsed to under $185 million. Adult-use legalization didn't kill the medical market exactly - it redirected it. Patients became general consumers. Operators stopped prioritizing patient-specific products. Registration fees and physician recommendation requirements added friction that recreational purchasing simply didn't impose. The medical designation, in a post-adult-use world, became commercially inert.
Federal rescheduling inverts that logic. Suddenly the M-designation carries a meaningful tax advantage that the A-designation does not - at least until the outcome of the June hearing is known. That's a real economic signal, and California's regulators read it fast.
State-by-State Ripple Effects and the D.C. Model Worth Watching
New Jersey offers a different wrinkle. The state launched adult-use sales in 2022 through its seven existing medical operators - a rollout that was deliberately cautious and left a dense population of adult-use entrepreneurs on the outside of the medical license structure. Now, following the federal order, New Jersey Cannabis Regulatory Commission officials may face pressure to open a pathway for those adult-use licensees to add medical designations. As cannabis consultant Susanna Puntel, a New Jersey national council member for the American Trade Association for Cannabis and Hemp, observed on LinkedIn after speaking with a CRC commissioner: a process for "rec dispensaries to 'expand' to medical" is now a conversation worth having.
That conversation is early - "trying to wrap their heads around the various moving pieces," in Puntel's own words - but the structural incentive is plain. States with large adult-use markets and comparatively thin medical programs have a reason to revisit their license architectures in ways they hadn't before.
The most instructive model may be Washington, D.C. A congressional rider inserted by Rep. Andy Harris, R-Md., has blocked the district from regulating adult-use retail since 2015, leaving all licensed cannabis sales classified as medical. In 2022, Mayor Muriel Bowser signed legislation allowing adults 21 and older - including tourists - to self-certify as medical patients without a doctor's recommendation. The effect was a de facto adult-use market operating entirely under a medical classification. Other states facing uncertainty about the June hearing outcome could adopt a version of this approach to capture Schedule III tax treatment for their broader licensee populations.
There's a dry irony buried in that possibility. Harris has been among the most vocal congressional opponents of rescheduling - arguing in a 2024 letter to the DEA that the HHS recommendation to move cannabis to Schedule III "lacks both substance and data." His rider, designed to suppress commercial cannabis in D.C., may instead have inadvertently produced the template other states use to expand Schedule III access. Policy has a way of doing that.
What the June Hearing Will - and Won't - Settle
The compressed administrative hearing process is designed to produce a final determination by July 15 on whether adult-use cannabis should also be removed from Section 280E's reach. What it will not do, regardless of outcome, is resolve the longer-term regulatory uncertainty that has defined this industry for a decade. If adult-use businesses win Schedule III treatment, the competitive pressure driving the current state-by-state scramble subsides. If they don't, expect the medical license to become the most actively pursued regulatory designation in markets where it remains available.
Either way, state regulators who spent years building adult-use frameworks largely separate from their medical programs are now being asked to reckon with the federal tax code as a structuring force - something most of them did not plan for. The DEA's refusal to engage states individually before releasing public guidance means each state is essentially reading the same information at the same time and improvising its own response. California moved in two weeks. New Jersey is still in conversation. Others haven't publicly acknowledged the question yet.
For operators, the calendar matters enormously. Medical licensees get relief starting Q1 2026. Every quarter between now and a final adult-use determination is a quarter of 280E exposure that a medical designation would eliminate. That math is not complicated. The regulatory window is open; the only question is how many states move fast enough to let operators climb through it.
